EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma

Reina Imase iD, Rie Sakakibara iD, Susumu Kirimura, Hironori Ishibashi, Kenichi Okubo, Yasunari Miyazaki iD

Thoracic Cancer · 2026-07 · 17 (13)

DOI: 10.1111/1759-7714.70343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 01.07.2026. Verfasst von Reina Imase und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Tumor Suppressor Proteins, Biomarkers, Tumor, Pleural Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, including JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Reliable predictive biomarkers for immune checkpoint inhibitors (ICIs) in pleural mesothelioma (PM) are lacking. Loss of BRCA1‐associated protein 1 (BAP1) is a frequent molecular alteration in PM and may influence the tumor immune microenvironment. We evaluated whether BAP1 loss is associated with clinical outcomes following immunotherapy.

Methods

We retrospectively analyzed 14 patients with PM who were treated with ICIs between April 2014 and May 2024. BAP1 status was assessed by immunohistochemical staining of resected tumor specimens. Patients were categorized into BAP1‐loss and BAP1‐positive groups. Progression‐free survival (PFS), overall survival (OS), response rate (RR), and disease control rate (DCR) were compared.

Results

BAP1 loss was observed in nine patients (64%). Median PFS was significantly longer in the BAP1‐loss group compared with the BAP1‐positive group (5.3 vs. 2.1 months; log‐rank p = 0.03). Median OS was also prolonged in the BAP1‐loss group (8.6 vs. 2.1 months; log‐rank p = 0.03). RR and DCR were numerically higher among patients with BAP1 loss.

Conclusion

BAP1 loss was associated with improved clinical outcomes following immunotherapy in PM. These findings support that a molecular profile that includes BAP1 deletion may serve as a biomarker for predicting response to immunotherapy in PM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin ThiolesteraseTumor Suppressor ProteinsBiomarkers, TumorPleural NeoplasmsImmunotherapyMesotheliomaMesothelioma, MalignantHumansFemaleRetrospective StudiesMaleAgedMiddle AgedPrognosis

Stichwörter der Autor:innen

BAP1immune checkpoint inhibitorimmunohistochemistryimmunotherapypleural mesothelioma

Substanzen

Ubiquitin ThiolesteraseBAP1 protein, humanTumor Suppressor ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Pathology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Thoracic Surgery, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Reina Imase, Rie Sakakibara, Yasunari Miyazaki

Förderung

  • Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, including JSPS KAKENHI

Zitieren

APA

Imase, R., Sakakibara, R., Kirimura, S., Ishibashi, H., Okubo, K., & Miyazaki, Y. (2026). BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma. Thoracic Cancer, 17(13). https://doi.org/10.1111/1759-7714.70343

Vancouver

Imase R, Sakakibara R, Kirimura S, Ishibashi H, Okubo K, Miyazaki Y. BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma. Thoracic Cancer. 2026;17(13). doi:10.1111/1759-7714.70343

BibTeX
@article{Imase2026,
  author = {Imase, Reina and Sakakibara, Rie and Kirimura, Susumu and Ishibashi, Hironori and Okubo, Kenichi and Miyazaki, Yasunari},
  title = {BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {13},
  doi = {10.1111/1759-7714.70343}
}
Kostenlos starten →